Navigation Links
Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University
Date:7/22/2010

WAYNE, N.J., July 22 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals is pleased to announce it will support the New Jersey Governor's School in the Sciences (NJGSS) at Drew University this summer.  This is the second year in a row that Bayer HealthCare Pharmaceuticals has sponsored the program, which is the longest running of the active Governor's schools.  

(Photo: http://photos.prnewswire.com/prnh/20100722/NY39266 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100722/NY39266 )

The NJGSS offers courses in neuroscience, cell biology, physics, mathematics, anthropology and chemistry. Eighty-five of the state's top math and science students representing 18 of New Jersey's 21 counties will participate in the three week program, which runs from July 11-31.  

"We challenge these outstanding high school juniors with an academic program that they usually would not experience until well into their college careers," said Dr. David Miyamoto, director of the NJGSS at Drew University.  "Students work together in teams on highly experiential research projects that lead to the writing of scientific-style papers and oral presentations of the work at a scientific-style conference."  

"As a company dedicated to science, we recognize the importance of unique programs like the NJGSS," said Sandra J. Oliver, vice president, public policy and government affairs at Bayer.  Located in Wayne, the company's aim is to develop and manufacture products that will improve human health by diagnosing, preventing and treating diseases.

Additionally, Making Science Make Sense® (MSMS) is Bayer's company-wide initiative that advances science literacy through hands-on, inquiry-based science education, employee volunteerism and a public education campaign. Currently, 12 Bayer sites around the country operate local MSMS programs, which together represent a national volunteer corps of more than 1,000 employees.

"Bayer HealthCare's generous support of the New Jersey Governor's School in the Sciences will continue to expose high school students throughout the state to opportunities and future careers in the sciences," said Governor Chris Christie.  "I want to thank Bayer for its contribution to this worthwhile program.  It is the support of local companies like Bayer that is invaluable in helping promote scientific learning, problem solving skills and leadership training to students throughout the Garden State."

About Drew University -- Founded in 1867, Drew is a selective, independent, coeducational university with a total enrollment of more than 2,700 students in its College of Liberal Arts, Caspersen School of Graduate Studies and Theological School.  Widely recognized for academic excellence and its tight-knit, diverse community, Drew is routinely listed among the nation's top colleges by The Princeton Review.  Having won Rhodes, Fulbright, Truman, Goldwater, Marshall and National Science Foundation scholarships, Drew students are among the best in the nation.  The university is one of three in New Jersey with a chapter of Phi Beta Kappa, the nation's most prestigious academic honor society.

About Bayer HealthCare Pharmaceuticals Inc. -- Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... North Carolina , 12 februari 2016 ... Inc. (AAI/CML), een toonaangevende leverancier van productie ... en biotechnologische industrieën, kondigt vandaag een uitbreiding ... mogelijkheden op haar locatie in ... vraag heeft geleid tot meerdere recente investeringen. ...
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset Protection, ... the beginning of the latest charity campaign in their community enrichment program. Art ... to this worthy cause are currently being accepted at: http://artexpressioninc.org/ . , ...
(Date:2/12/2016)... ... ... Miami Dental Specialists is excited to bring patients the choice of ceramic, ... Miami Dental Specialists will offer the non-metal implants as a safe, holistic and hygienic ... by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to Miami. ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... foods choices that promote eye health. These articles generally list between five and ... health advocate Sharon Kleyne endorses every one of these lists and believes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have ... possibilities. CertainTeed, North America’s leading brand of building products, has improved upon its ... in the mobile version of the ColorView® Exterior Style and Color Selector. Created ...
Breaking Medicine News(10 mins):